

Special Issue

Vaccination Coverage, Efficacy and Attitude in Targeted Risk Groups

Message from the Guest Editors

We are soliciting articles for a Special Issue of MDPI *Vaccines*, which is entitled “Vaccination coverage, efficacy and attitude in targeted risk groups”.

Vaccination, if available, has proven to be the most effective way of preventing and reducing the burden of many infectious diseases. However, two of the current biggest challenges in the field of vaccinology are the upcoming trend of vaccine hesitancy and the decreased efficacy in risk groups. In fact, if we are able to produce effective and safe vaccines but their uptake is low, the desired effect will not be achieved. Furthermore, vaccines effective in healthy adults could have a decreased effect in the immunocompromised and elderly.

An improved understanding of drivers of vaccine uptake and efficacy will enhance targeted interventions. In addition, due to the high heterogeneity of risk groups in general, one could learn a lot about the efficacy of interventions to increase vaccination uptake and efficacy.

Guest Editors

Dr. Marco Goeijenbier

Department of Intensive Care, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands

Prof. Eric C.M. van Gorp

Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/47554

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).